報價延遲最少15分鐘:2024/12/23 22:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.63/-2.10
|
|
企業價值
1.00B
|
| 資產負債 |
|
每股賬面淨值
0.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
64.70M
|
|
每股收益
1.61
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline ofautologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |